National Institute on Aging, National Institutes of Health, Biomedical Research Center, Baltimore, MD 21224-6825, USA.
Talanta. 2010 Jun 15;81(4-5):1477-81. doi: 10.1016/j.talanta.2010.02.055. Epub 2010 Feb 25.
CMAC (cellular membrane affinity chromatography columns) have been developed for the study of the human multidrug transporters MRP1, MRP2 and the breast cancer resistance protein (BCRP). The columns were constructed using the immobilized artificial membrane (IAM) stationary phase and cellular membrane fragments obtained from Spodoptera frugiperda (Sf9) cells that had been stably transfected with human Mrp1, Mrp2 or Bcrp cDNA, using a baculovirus expression system. The resulting CMAC(Sf9(MRP1)), CMAC(Sf9(MRP2)) and CMAC(Sf9(BCRP)) columns and a control column produced using membrane fragments from non-transfected Sf9 cells, CMAC(Sf9), were characterized using frontal affinity chromatography using [(3)H]-etoposide as the marker ligand and etoposide, benzbromarone and MK571 as the displacers on the CMAC(Sf9(MRP1)) column, etoposide and furosemide on the CMAC(Sf9(MRP2)) column and etoposide and fumitremorgin C on the CMAC(Sf9(BCPR)) column. The binding affinities (K(i) values) obtained from the chromatographic studies were consistent with the data obtained using non-chromatographic techniques and the results indicate that the immobilized MRP1, MRP2 and BCRP transporters retained their ability to selectively bind known ligands. (S)-verapamil displaced [(3)H]-etoposide on the CMAC(Sf9(MRP1)) column to a greater extent than (R)-verapamil and the relative IC(50) values of the enantiomers were calculated using the changes in the retention times of the marker. The observed enantioselectivity and calculated IC(50) values were consistent with previously reported data. The results indicated that the CMAC(Sf9(MRP1)), CMAC(Sf9(MRP2)) and CMAC(Sf9(BCRP)) columns can be used for the study of binding to the MRP1, MRP2 and BCRP transporters and that membranes from the Sf9 cell line can be used to prepare CMAC columns. This is the first example of the use of membranes from a non-mammalian cell line in an affinity chromatographic system.
CMAC(细胞膜亲和色谱柱)已被开发用于研究人类多药转运蛋白 MRP1、MRP2 和乳腺癌耐药蛋白(BCRP)。这些柱子是使用固定化人工膜(IAM)固定相和从稳定转染人 Mrp1、Mrp2 或 Bcrp cDNA 的 Spodoptera frugiperda(Sf9)细胞获得的细胞膜片段构建的,使用杆状病毒表达系统。由此产生的 CMAC(Sf9(MRP1))、CMAC(Sf9(MRP2))和 CMAC(Sf9(BCRP))柱子以及使用非转染 Sf9 细胞的膜片段制备的对照柱 CMAC(Sf9),使用 [(3)H]-依托泊苷作为标记配体和依托泊苷、苯溴马隆和 MK571 作为 CMAC(Sf9(MRP1))柱上的置换剂、依托泊苷和呋塞米在 CMAC(Sf9(MRP2))柱上和依托泊苷和 fumitremorgin C 在 CMAC(Sf9(BCPR))柱上进行前沿亲和色谱分析。从色谱研究中获得的结合亲和力(K(i) 值)与使用非色谱技术获得的数据一致,结果表明固定化的 MRP1、MRP2 和 BCRP 转运蛋白保留了选择性结合已知配体的能力。(S)-维拉帕米在 CMAC(Sf9(MRP1))柱上对 [(3)H]-依托泊苷的置换程度大于 (R)-维拉帕米,并用标记物保留时间的变化计算对映体的相对 IC(50) 值。观察到的对映选择性和计算的 IC(50) 值与先前报道的数据一致。结果表明,CMAC(Sf9(MRP1))、CMAC(Sf9(MRP2))和 CMAC(Sf9(BCRP))柱子可用于研究与 MRP1、MRP2 和 BCRP 转运蛋白的结合,并且 Sf9 细胞系的膜可用于制备 CMAC 柱子。这是首次在亲和色谱系统中使用非哺乳动物细胞系的膜。